TUSTIN, CA--(Marketwire - May 14, 2010) - Through its US-based subsidiary AMDL Diagnostics Inc., Radient Pharmaceuticals Corporation (RPC) (NYSE Amex: RPC) announced today its executive management will be in India May 20, 2010 through May 25, 2010 with the goal of accelerating the commercialization of RPC’s Onko-Sure™ in vitro diagnostic (IVD) cancer test in India through distribution partnerships with Gaur Diagno (New Delhi).
More specifically, RPC’s executive management team will be solidifying expanded partnership agreements for the sales and marketing of Onko-Sure test kits with Gaur Diagno; and the development of clinical trials for RPC’s Combination Immunogene Therapy (CIT) technology with Jaiva Technologies.
According to Mr. Douglas MacLellan, Chairman and CEO of Radient Pharmaceuticals, “Measurable progress for Onko-Sure cancer testing is of the utmost importance for Radient Pharmaceuticals and its employees, customers, partners and shareholders. We have scheduled meetings with a highly anticipated program launch with key government officials in India in support of the commercialization of our US FDA approved Onko-Sure IVD cancer test. Through discussions, we anticipate receiving Indian government support in various regions to implement Onko-Sure as a general cancer screening tool in India -- one of the first major initiatives for Onko-Sure as a cancer testing/screening tool. India is top tier market for RPC’s Onko-Sure IVD cancer test.”
About Onko-Sure™:
Onko-Sure™ is a simple, non-invasive, patent-pending and regulatory-approved in vitro test for use as an aid in early detection of cancer that enables physicians and their patients to effectively monitor and/or detect certain types of cancers by measuring the accumulation of specific breakdown products in the blood called Fibrin and Fibrinogen Degradation Products (FDP). FDP levels rise dramatically with the progression of cancer. Onko-Sure™ is approved by the US FDA for the monitoring of colorectal cancer and by Health Canada as a lung cancer screen and lung cancer monitoring test.
About CIT:
CIT is a proprietary, US-patented technology owned by Radient Pharmaceuticals. Used as a cancer therapy and vaccine, CIT both builds the body’s immune system and destroys cancers simultaneously. The treatment involves injecting the patient with an attenuated viral vector carrying a combination of two genes, B7-2 and GM-CSF. The standard approach in utilizing gene therapy to combat cancer has been to attempt to replace defective genes in cancer cells, which has proven to be impractical because of the number of genes involved. The GM-CSF gene enters the patient’s tumor and genetically alters the tumor so that it attracts the patient’s antigen presenting cells (dendritic cells that capture antigens), which activate tumor-specific T-cells. The B7-2 gene also enters the patient’s tumor and genetically alters it, so it can stimulate a larger number of, and stronger, T-cells to fight the cancer.
For additional information on Radient Pharmaceuticals, ADI and its portfolio of products visit the Company’s corporate website at www.Radient-Pharma.com. For Investor Relations information contact Kristine Szarkowitz at IR@Radient-Pharma.com or 1.206.310.5323.
About Radient Pharmaceuticals:
Headquartered in Tustin, California, Radient Pharmaceuticals Corporation is an integrated pharmaceutical company devoted to the research, development, manufacturing, and marketing of in-vitro diagnostic products.
About Gaur Diagno:
Gaur Diagno is a New Delhi, India based pharmaceutical distributor. Additional information can be found on their website at http://www.gaurdiagno.com/.
About Jaiva Technologies:
Jaiva Technologies is a US-based multinational biotechnology company focused on the research and development, distribution, marketing and sales of promising third-party healthcare technology products, including RPC’s CIT cancer therapy and vaccine.
Forward Looking Statements:
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: The statements contained in this document include certain predictions and projections that may be considered forward-looking statements under securities law. These statements involve a number of important risks and uncertainties that could cause actual results to differ materially including, but not limited to, the performance of joint venture partners, as well as other economic, competitive and technological factors involving the Company’s operations, markets, services, products, and prices. With respect to Radient Pharmaceuticals Corporation, except for the historical information contained herein, the matters discussed in this document are forward-looking statements involving risks and uncertainties that could cause actual results to differ materially from those in such forward-looking statements.
Radient Pharma Contact:
Kristine Szarkowitz
Director-Investor Relations
Email Contact
Tel: 206.310.5323
Digg this
Bookmark with del.icio.us
Add to Newsvine
Technorati: 
